Moreover, patient-derived T cells are genetically engineered in vitro to express chimeric antigen receptors (CARs) that directly recognize targets on AML blasts, such as CD33, CD123, etc. Additional well-designed clinical trials are needed to determine which BsAb molecule formats and specificities will be most clinically useful to treat myeloid neoplasms and to compare their performance to CAR T cells. The gene discussed is CD33; the disease is acute myeloid leukemia.